

## Hepatitis-E-Virus: Anstehende Konsequenzen für die Transfusionsmedizin

1. Nagashima S, Takahashi M. et al., Characterization of the Quasi-Enveloped Hepatitis E Virus Particles Released by the Cellular Exosomal Pathway. *J Virol*. 2017 Oct 27;91(22). pii: e00822-17.
2. Khuroo MS, Khuroo NS, Transmission of Hepatitis E Virus in Developing Countries. *Viruses*. 2016 Sep 20;8(9). pii: E253.
3. Pérez-Gracia MT, García M., et.al., Current Knowledge on Hepatitis E. *J Clin Transl Hepatol*. 2015 Jun 28;3(2):117-26. doi: 10.14218/JCTH.2015.00009. Epub 2015 Jun 15.
4. Faber MS, Wenzel JJ, Jilg W, Thamm M, Höhle M, Stark ., Hepatitis E virus seroprevalence among adults, Germany. *Emerg Infect Dis*. 2012 Oct;18(10):1654-7. doi: 10.3201/eid1810.111756.
5. Mahrt H, Schemmerer M, Behrens G, Leitzmann M, Jilg W, Wenzel JJ, Continuous decline of hepatitis E virus seroprevalence in southern Germany despite increasing notifications, 2003-2015. *Emerg Microbes Infect*. 2018 Jul 25;7(1):133. doi: 10.1038/s41426-018-0136-8.
6. Khuroo MS, Khuroo NS, Hepatitis E: Discovery, global impact, control and cure. *World J Gastroenterol*. 2016 Aug 21;22(31):7030-45. doi: 10.3748/wjg.v22.i31.7030.
7. Wedemeyer H, Cornberg M., The hepatitis E virus: a likely cause of extrahepatic diseases! *Liver Int*. 2016 Apr;36(4):473-6. doi: 10.1111/liv.13088.
8. Kamar N, Pischke S, Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment. *Cold Spring Harb Perspect Med*. 2018 May 7. pii: a031872. doi: 10.1101/cshperspect.a031872. [Epub ahead of print]
9. Kamar N, Selves J et.al., Hepatitis E virus and chronic hepatitis in organ-transplant recipients. *N Engl J Med*. 2008 Feb 21;358(8):811-7. doi: 10.1056/NEJMoa0706992.
10. Ikram A, Hakim MS et. al., Genotype-specific acquisition, evolution and adaptation of characteristic mutations in hepatitis E virus. *Virulence*. 2018 Jan 1;9(1):121-132. doi: 10.1080/21505594.2017.1358349. Epub 2017 Aug 18.
11. Choi M, Hofmann J et. al., Prevalence and Clinical Correlates of Chronic Hepatitis E Infection in German Renal Transplant Recipients With Elevated Liver Enzymes. *Transplant Direct*. 2018 Feb 2;4(2):e341. doi: 10.1097/TXD.0000000000000758. eCollection 2018 Feb.
12. Hewitt PE, Ijaz S, Brailsford, Su R, Brett I, Dicks S, Haywood B, Kennedy ITR, Kitchen A, Patel P, Poh J, Russell K, Tettmar KI, Tossell J, Ushiro-Lumb I, Tedder RS. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. *The Lancet* 2014 Jul 28;384(9956):1766-1773.
13. Frange P, Roque-Afonso AM, Neven B, Moshous D, Touzot F, Cavazzana M, Fischer A, Leruez-Ville M, Blanche S. Hepatitis E virus in hematopoietic stem cell donors: Towards a systematic HEV screening of donors? *J Infect* 2015 Jul; 71(1):141-144.
14. Vollmer T, Knabbe C, Dreier J. Knowledge Is Safety: The Time Is Ripe for Hepatitis E Virus Blood Donor Screening. *Transfus Med Hemother* 2016;43:425–427.
15. Satake M, Matsubayashi Keiji, Hoshi Y, Taira R, Furui Y, Kokudo N, Akamatsu N, Yoshizumi T, Ohkohchi N, Okamoto H Miyoshi M, Tamura A, Fuse K, Tadokoro K. Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression. *Transfusion* 2017 Jan 31; 57:280-288.
16. Westhölter D, Hiller J, Denzer U, Polywka S, Ayuk F, Rybczynski M, Horvatits T, Gundlach S, Fischer N, Addo MM, Peine S, Göke B, Lohse AW, Lütgehetmann M, Pischke S. HEV positive blood donations represent a relevant infection risk for immunosuppressed recipients. *J Hepatol* 2018 Jul; 69(1):36-42
17. Domanović D, Tedder R, Blümel J, Zaaijer H, Gallian P, Niederhauser C, Saulea Oliveras S, O'Riordan J, Boland F, Harritshøj L, Nascimento MSJ, Ciccaglione AR, Politis C, Adlhoch C, Flan B, Oualikene-Gonin W, Rautmann G, Strengers P, Hewitt P. Hepatitis E and blood donation safety in selected European countries: a shift to screening? *Euro Surveill* 2017; 22(16):pii=30514.
18. Pauli G, Aepfelbacher Martin, Bauerfeind U, Blümel J, Burger R, Gärtner B, Gröner A, Gürtler L, Heiden M, Hildebrandt M, Jansen B, Offergeld R, Schlenkrich U, Schottstedt V, Seitz R, Strobel J, Willkommen H, Baylis SA. Hepatitis E Virus. *Transfus Med Hemother* 2015;42:247–265.
19. Kamp C, Blümel J, Baylis SA, Bekeredjian-Ding I, Chudy M, Heiden M, Henseler O, Keller-Stanislawski B, Vos AS de, Funk MB. Impact of hepatitis E virus testing on the safety of blood components in Germany – results of a simulation study. *Vox Sang* 2018;113:811-813.
20. Harritshøj LH, Holm DK, Saekmose SG, Jensen BA, Hogema BM, Fischer TK, et al. Low transfusion transmission of hepatitis E among 25,637 single-donation, nucleic acid-tested blood donors. *Transfusion*. 2016;56(9):2225-2232.

21. Gallian P, Lhomme S, Piquet Y, Sauné K, Abravanel F, Assal A, et al. Hepatitis E virus infections in blood donors, France. *Emerg Infect Dis.* 2014;20(11):1914-1917.
22. Vollmer T, Diekmann J, Johne R, Eberhardt M, Knabbe C, Dreier J. Novel approach for detection of hepatitis E virus infection in German blood donors. *J Clin Microbiol.* 2012;50(8):2708-2713.
23. Hogema BM, Molier M, Sjerps M, de Waal M, van Swieten P, van de Laar T, et al. Incidence and duration of hepatitis E virus infection in Dutch blood donors. *Transfusion.* 2016;56(3):722-728.
24. Sauleda S, Ong E, Bes M, Janssen A, Cory R, Babizki M, et al. Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from Catalonia (Spain). *Transfusion.* 2015;55(5):972-979.

## Störung der blutgruppenserologischen Untersuchungen durch therapeutische monoklonale Antikörper

1. Swanson JL, Issitt CH, Mann EW, Condie RM, Simmons RL, McCullough J. Resolution of red cell compatibility testing problems in patients receiving anti-lymphoblast or anti-thymocyte globulin. *Transfusion* 1984;24:141-3.
2. Enkel, S., Nowak-Harnau, S., and Bakchoul, T. Daratumumab and Isatuximab - two different treatments for patients with multiple myeloma interfering with compatibility testing for blood transfusion. *Transfusion Medicine and Hemotherapie* 2018;45:13-14.
3. Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, Vaisitti T, Aydin S. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. *Physiol Rev* 2008;88:841-86.
4. Zhao YJ, Lam CM, Lee HC. The membrane-bound enzyme CD38 exists in two opposing orientations. *Sci Signal* 2012;5:ra67.
5. Hardingham GE, Chawla S, Johnson CM, Bading H. Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression. *Nature* 1997;385:260-5.
6. Deaglio S, Capobianco A, Bergui L, Durig J, Morabito F, Duhrsen U, Malavasi F. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. *Blood* 2003;102:2146-55.
7. Morandi F, Horenstein AL, Costa F, Giuliani N, Pistoia V, Malavasi F. CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma. *Front Immunol* 2018;9:2722.
8. Oostendorp M, Lammerts van Bueren JJ, Doshi P, Khan I, Ahmadi T, Parren PW, van Solinge WW, De Vooght KM. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. *Transfusion* 2015;55:1555-62.
9. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med* 2016;375:1319-31.
10. Sullivan HC, Gerner-Smidt C, Nooka AK, Arthur CM, Thompson L, Mener A, Patel SR, Yee M, Fasano RM, Josephson CD, et al. Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. *Blood* 2017;129:3033-7.
11. Empfehlung zum Vorgehen bei serologischen Störungen durch den therapeutischen monoklonalen Antikörper Daratumumab (Darzalex). Stand: 01.07.2016 Sektion Immunhämatologie und Immungenetik. 2016. <https://dgti.de/service/news/stellungnahmen-der-dgti.html>.
12. Schneeweiß C, Grüger D, Heuft H-G. DaraEx verhindert Daratumumab-Interferenz im indirekten Antihumanglobulintest. *Transfusionsmedizin* 2017;7:229-32.
13. Rosner, A., Chocholi, I., and Hölig, K. First experiences with DaraEx in cross-matching red blood cell concentrates under Daratumumab therapy. *Transfus Med Hemother* 2018;45:12.
14. Leon Crottet, S., Lobsiger, S., and Hustinx, H. DaraEx: a new approach to solve the interference of Daratumumab in the indirect antiglobulin test. *Transfus Med Hemother* 2018;45:61.
15. McCudden C, Axel AE, Slaets D, Dejoie T, Clemens PL, Frans S, Bald J, Plesner T, Jacobs JF, van de Donk NW, et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. *Clin Chem Lab Med* 2016;54:1095-104.
16. Seltsam A, Grueger D, Blasczyk R, Flegel WA. Easy identification of antibodies to high-prevalence Scianna antigens and detection of admixed alloantibodies using soluble recombinant Scianna protein. *Transfusion* 2009;49:2090-6.
17. European Medicines Agency. Darzalex product information 2019; [https://www.ema.europa.eu/documents/product-information/darzalex-epar-product-information\\_de.pdf](https://www.ema.europa.eu/documents/product-information/darzalex-epar-product-information_de.pdf).
18. Binda, M., Favoloro, V., Piel, N., Berry, J. D., and Schwind, P. Detection of masked irregular antibodies in anti-CD38 containing plasma after neutralization with a novel recombinant CD38. *Transfus Med Hemother* 2018;45:12-13.
19. Tremblay T, Baillargeon N, Chevrier M, Loubaki L. New approaches to eliminate CD38 monoclonal antibodies related interference in pre-transfusion testing. *Vox Sang* 2018;113:15.
20. Carreno-Tarragona G, Cedena T, Montejano L, Alonso R, Miras F, Valeri A, Rivero A, Lahuerta JJ, Martinez-Lopez J. Papain-treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti-CD38-based therapies. *Transfus Med* 2018.
21. Hustinx H. 2019. Persönliche Kommunikation

22. Selleng, K., Denker, P., Doshi, P., and Greinacher, A. Performance qualification of the pretransfusional antibody screening test of plasma containing Daratumumab (anti-CD 38 antibody) after DTT-treatment of the test cells using gel card and Capture® . *Transfus Med Hemother* 2017;44:57.
23. Werle, E., Ziebart, J., Wasmund, E., and Eske-Pogodda, K. Daratumumab interference in indirect antiglobulin testing is eliminated by use of daratumumab Fab-fragments. *Transfusion Medicine and Hemotherapie* 2018;45:13.
24. Schuetz C, Hoenig M, Moshous D, Weinstock C, Castelle M, Bendavid M, Shimano K, Tolbert V, Schulz AS, Dvorak CC. Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. *Blood Adv* 2018;2:2550-3.
25. Kaplon H, Reichert JM. Antibodies to watch in 2019. *MAbs* 2018. ePub ahead of Print
26. Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. *N Engl J Med* 2018;379:1711-21.
27. Velliquette RW, Aeschlimann J, Kirkegaard J, Shakarian G, Lomas-Francis C, Westhoff CM. Monoclonal anti-CD47 interference in red cell and platelet testing. *Transfusion* 2018. ePub ahead of Print

## Blut und Bomben – die Blutversorgung bei Großschadensereignissen aus der Sicht eines Blutspendedienstes

1. Zeiler, T., & Deitenbeck, R. (2018). "Nationale Blutreserve"? In S. R. Lüder & B. Stahlhut (Eds.), Konturen einer Gesundheits-Sicherheitspolitik (pp. 139-147). Berlin: Berliner Wissenschafts-Verlag.
2. Ramsey, G. (2017). Blood component transfusions in mass casualty events. *Vox Sang*, 112(7), 648-659. doi:10.1111/vox.12564
3. Doughty, H., Glasgow, S., & Kristoffersen, E. (2016). Mass casualty events: blood transfusion emergency preparedness across the continuum of care. *Transfusion*, 56 Suppl 2, S208-216. doi:10.1111/trf.13488
4. Quillen, K., & Luckey, C. J. (2014). Blood and Bombs: blood use after the Boston Marathon Bombing of April 15, 2013. *Transfusion*, 54, 1202-1203.
5. Linden, J. V., Davey, R., & Burch, J. W. (2002). The September 11, 2001 disaster and the New York blood supply. *Transfusion*, 42, 1385-1387.
6. Compennolle, V., Najdovski, T., I., D. B., & Vanderkerckhove, P. (2017). Lessons for blood services following the Brussels terrorist attacks in March 2016. *ISBT Science Series*, 13, 47-50.
7. Noel, S., Francois, A., Le Failler, F., Charpentier, F., Baudonnet, T., Bierling, P., ... Et.al. (2017). Lessons learned from Paris and Niece. *ISBT Science Series*, 13, 35-46.

## Transfusionsmedizin in der Mongolei und Handlungsbedarf hinsichtlich der Forschung

1. <https://www.aerzteblatt.de/nachrichten/96753/Weltweiter-Kampf-gegen-Hepatitis-geht-nur-langsam-voran>
2. <https://www.blutspendedienst.com/blutspende/blut-blutgruppen/verteilung-der-blutgruppen>
3. Neonatale Versorgung, Human Development Reports, 2018 (in mongolisch)
4. Nationales Gesundheitsregister, 2017 (in mongolisch)
5. Bekhbold Dashtseren, Bayarmagnai Bold, Naranjargal Dashdorj, Dawghadorj Yagaanbuyant, Department of Infecious Disease, HSUM, Onom Foundation "Epidemiological Study of Prevalence and Risk Factors for Viral Hepatitis among Apparently Healthy Mongolians", 2016, in english
6. Erdenebyayr Namjil, Trends in the prevalence of transfusion transmitted infections among blood donors, 2018 (in english)
7. WHO Report, Viral hepatitis in Mongolia, Situation and Response, 2015
8. Tserenpuntsag B, Ouynbileg L, Nelson K, McNutt LA. Prevalence of infectious diseases among Mongolian blood donors. J Infect Dev Ctries. 2008 Feb 1;2(1):73-5
9. Baatarkhuu O, Gerelchimeg T, Munkh-Orshikh D, Batsukh B, Sarangua G, Amarsanaa J. Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia. Euroasian J Hepatogastroenterol. 2018 Jan-Jun;8(1):57-62.